文献速递胸部肿瘤放疗放疗物理与技术

合成CT用于肺癌磁共振-only放疗计划的剂量学评估

Dosimetric evaluation of synthetic CT for magnetic resonance-only based radiotherapy planning of lung cancer.
PubMed 文献 · Radiat Oncol · 2017-06-26

结果显示synCT与CT的PTV剂量差异均值在-0.1%至0.4%之间,OAR剂量差异小,3D gamma分析通过率达99.3%±1.1%,表明synCT可用于肺癌放疗计划剂量计算且精度与标准CT相当。

要点

  • synCT与CT的PTV剂量差异均值在-0.1%至0.4%之间,OAR剂量差异小。
  • 基于肿瘤大小和位置分组,除肺尖靶区脊髓最大剂量(p=0.001)外无显著差异。
  • 2%/2 mm gamma分析通过率为99.3%±1.1%,支持MR-only工作流发展。

核心结论

  • 基于Dixon MRI生成的synCT用于肺癌放疗计划时,剂量计算精度与标准CT相当。
  • synCT与CT计算的剂量学一致性支持进一步开发MR-only放疗工作流。

研究设计与样本

  • 利用Dixon MR图像衍生的衰减图谱和图谱法方法创建synCT。
  • 在synCT上优化肺癌放疗计划后复制到配准CT(planCT)进行剂量计算。
  • 计划靶区(PTV)设置三种大小和四个不同肺部位置进行照射。
  • 进行剂量体积指标比较和3D gamma分析以评估synCT与CT剂量分布的一致性。

主要发现

  • 所有计划中synCT与CT的PTV剂量差异均值:D95为-0.1%±0.4%,D98为0.1%±0.5%,D100为0.4%±0.5%。
  • 危及器官(OAR)剂量平均差异:脊髓最大剂量-0.14±0.07 Gy,肺V20为0.0%±0.1%,心脏V40为-0.1%±0.2%。
  • 按肿瘤大小和位置分组,PTV和OAR剂量体积指标无显著差异(p>0.05),但靶区位于肺尖时脊髓最大剂量差异显著(p=0.001)。
  • Gamma分析显示每个计划在2%/2 mm标准下通过率为99.3%±1.1%。

关键数值与推荐

  • PTV剂量指标D95、D98、D100的差异均值分别为-0.1%±0.4%、0.1%±0.5%、0.4%±0.5%。
  • 脊髓最大剂量平均差异-0.14±0.07 Gy,肺V20平均差异0.0%±0.1%,心脏V40平均差异-0.1%±0.2%。
  • 除肺尖靶区脊髓最大剂量(p=0.001)外,其余剂量体积指标组间比较p>0.05。
  • 3D gamma分析采用2%/2 mm(剂量差异/一致性距离)标准,通过率99.3%±1.1%。

临床怎么用

  • synCT可用于肺癌放疗计划剂量计算,精度与标准CT相当。
  • 对于肺尖部位靶区,需关注脊髓最大剂量在synCT与CT间的差异。
  • 研究结果支持进一步开发MR-only工作流用于肺癌放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interest in MR-only treatment planning for radiation therapy is growing rapidly with the emergence of integrated MRI/linear accelerator technology. The purpose of this study was to evaluate the feasibility of using synthetic CT images generated from conventional Dixon-based MRI scans for radiation treatment planning of lung cancer. METHODS: Eleven patients who underwent whole-body PET/MR imaging following a PET/CT exam were randomly selected from an ongoing prospective IRB-approved study. Attenuation maps derived from the Dixon MR Images and atlas-based method was used to create CT data (synCT). Treatment planning for radiation treatment of lung cancer was optimized on the synCT and subsequently copied to the registered CT (planCT) for dose calculation. Planning target volumes (PTVs) with three sizes and four different locations in the lung were planned for irradiation. The dose-volume metrics comparison and 3D gamma analysis were performed to assess agreement between the synCT and CT calculated dose distributions. RESULTS: Mean differences between PTV doses on synCT and CT across all the plans were -0.1% ± 0.4%, 0.1% ± 0.5%, and 0.4% ± 0.5% for D95, D98 and D100, respectively. Difference in dose between the two datasets for organs at risk (OARs) had average differences of -0.14 ± 0.07 Gy, 0.0% ± 0.1%, and -0.1% ± 0.2% for maximum spinal cord, lung V20, and heart V40 respectively. In patient groups based on tumor size and location, no significant differences were observed in the PTV and OARs dose-volume metrics (p > 0.05), except for the maximum spinal-cord dose when the target volumes were located at the lung apex (p = 0.001). Gamma analysis revealed a pass rate of 99.3% ± 1.1% for 2%/2 mm (dose difference/distance to agreement) acceptance criteria in every plan. CONCLUSIONS: The synCT generated from Dixon-based MRI allows for dose calculation of comparable accuracy to the standard CT for lung cancer treatment planning. The dosimetric agreement between synCT and CT calculated doses warrants further development of a MR-only workflow for radiotherapy of lung cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang H, Chandarana H, Block KT, et al. Dosimetric evaluation of synthetic CT for magnetic resonance-only based radiotherapy planning of lung cancer. Radiat Oncol. 2017. PMID: 28651599. doi:10.1186/s13014-017-0845-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。